Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT01747096
TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
Overview
Evaluation of the diagnostic performance of PET / CT with 68Ga-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors with comparison with other techniques used in routine clinical practice (octreoscan ® ; multiphase SPECT / CT, MRI or endoscopy). Therapeutic impact and safety of PET / CT with 68Ga-DOTANOC will also be assessed. Expected results are a confirmation of the superiority of 68Ga-PET DOTANOC versus scintigraphy octreoscan ®, with a potential impact on the therapeutic management of patients.
Sponsor
Nantes University Hospital
Phase
N/A
Contacts
Catherine Ansquer, MD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT01747096Eligibility
Inclusion
- Clinical or biological syndrome strongly suggestive of digestive endocrine disease without identification of lesions with conventional imaging
- Fortuitous discovery of suggestive tumors of TE-GEP with well documented conventional imaging (multiphase CT; MRI, US endoscopy) associated or not associated with clinical or biological signs of TE-GEP tumors (increase in tumor markers) OR
- Histologically proven GEP-TE (WHO classification 2010 (26) well differentiated in the initial staging OR
- Affiliation to an insurance
- Suspicion of recurrence or progression of well differentiated TE-GEP tumors on conventional imaging or laboratory tests (increase in tumor markers) OR
Exclusion
- malignancy except basal cell cancers and cancer in situ of the cervix
- Restlessness, inability to lie still hold at least 1 hour; Claustrophobia
- Patients who had a CT scan without injection of contrast material can not participate in the study
- TE GEP tumor not differentiated
- Multiple endocrine neoplasia
- Persons protected by law
- Treatment with radiotherapy, chemotherapy or other antitumor treatment within 6 weeks of previous morphological and scintigraphic examinations. In case of treatment with somatostatin analogues delayed, scans will be performed 4 weeks after the last injection. However, a shorter period may be observed to avoid to do again the initial assessment exams.
- Contraindication of injection of a contrast agent necessary for the production of multiphase scanner.
- Pregnancy and lactation
- Poor compliance predictable or inability to undergo medical test for geographical, social or psychological
Share your feedback
Help us improve your experience